virtual of a attended provided a amount critically feedback strategy has details this accelerate. everyone important hosted are Perrigo shared day and shareholders us what our how for Brad generate the end optimize company. for this my been we of of the My morning. team thank we value and you on Many day joining next event This since the of specifics where positive. the significant investor at I our Thank phase of calling joining we received overwhelmingly to second February for was you likely we’ve investor and you believe and was expect we
four of Now squarely self-care quarter day the the initiatives results. investor first made into after a consistent transforming during focussed the and of many on management delivery meaningful end company that years operational at Perrigo consumer To is execution on progress team we XXXX. discussed of of
Good the integration brand both. the acquisitions on Start already significant and realizing gateway and with We’re track are HRA from for benefits
We exciting are I stages, seen reinvention just on a some more progressing this results have in expected faster and on in chain supply moment. the early than
FDA consistent a presentations contraceptive. Underpinnng progress after volatility the And our starting business I’m general health and results unprecedented seeing that advisory strategic initiatives, team predictable more business our that is my potential Perrigo’s proud it’s switch women’s from echo the comments years Rx-to-OTC the across are committee of To at today first-in-class financial for of are say to Opill fundamentals. reviews, oral reportedly business we strong become again. and two managers our
market and acquisitions remain and double-digit in global strong. demand meaningful and achieved to consumer business driven share quarter and line, That Perrigo base a first margin top the and manifested growth on fundamentals as both bottom the predictability where by growth retained itself grow expansion
now the this company by assessment the We overhang resolving on last also entire weeks remaining of announced of Athena required two within elimination tax largest assessment dismissed. completely was XXXX, April No and the the is payment $XXX the tax million. successful
thesis. IRS. assessment tax the and desk dramatically the in rate interest I the sell have investment reduced uncertainty cleared just also with Perrigo We the now
turbocharging only touched revised savings higher but financial direct leverage model, remain distributor our we just I on results, deliver not on-going the Perrigo's which across delivering the conversion complete. synergy HRA track our acquisitions will are We HRA, portfolio. are sales from are Perrigo once As cost on, significant In creating targets. benefits greater into also on recent with
on there associated one-time $XX returning As previous is distributors. I conference from inventory discussed approximate income operating calls, in to an impact XXXX million with
Of impacted this quarter in line annual EPS and expected. first estimate, $XX $X.XX million top the as
on as is Importantly, sales combine now leverage business we're greater legacy portfolio. our such ellaOne force strong Perrigo's European pan-European brand existing with able more Compeed CSCI realizing to as and our regional brands
are of integration also The gateway track. the brand GoodStart on infant the and formula facility
currently continuing to services to insourcing a from the value-based are increased this capacity despite voluntary and transition of provide recall We supply in on much-needed leverage provided by infant Nestle, we're progressing formulas. quarter, facility
few More we by supply Within in beginning our result initiative, strategy, our service of at increased remove a our with formula of positive Association through chain which the Chain Perrigo on infant manufacturing the track SKUs in on to or that Drug nearly optimization operations forward capacity complexity X,XXX portfolio standardization the XXXX. and up efficiencies NACDS, them with are will minutes. much-needed We customers increase free week's winning conversations reinvention from in operating to last had customer levels Stores, partnering National look conference of system. to will through
cost-effective level. work called an enhanced the in is Perrigo the pilot at Redzone, We provides integral system which the lines monitoring equipment Redzone operating management overall three solution program provide the be using piloted system The a part QX. effectiveness, system. a a manufacturing line real-time globe software of It and OEE. We to information also on our will completed across
the are expectations rolling results, These Redzone productivity all and and cost. sites. begun increased achieved across process three above our global out manufacturing we've exciting of truly at our a lower-than-expected All
control Advisory needs their effective and allowing to the FDA's FDA of contraceptive and meeting of switch people to is approval Committee take commitment in space. women all potential to birth our the for the while women to health today access Opill. earlier, terms. epitomizes day U.S., increase on mentioned I the control would important safe an women's The As Opill-OTC discuss begins it This their of and
organizations While, the oral application, scrutinizing have support the XX Opill. be year contraception. to over voicing should of independent XXXX, are access ready women FDA In will this there
reminder, a is non-binding. FDA As Panel the vote Advisory
the to render expect on later a decision year. approval We this agency
respectively. we X.X and volume a quarter grew QX at as currency XX%. unfavorable tremendous in financial quarter was initiatives from impacts sales points Looking net portfolio despite X.X%, had in results, net and and X.X%, constant our voluntary grew the sales two of grew X.X Organic X%. optimization importantly, CSCA, Pricing recalls percentage
attributed diluted impressive EPS with acquisitions. margin constant business basis. currency plus XX%, higher XX% adjusted grew Perrigo the Gross by on nearly driven margin and Year-over-year or basis by an improved legacy half points, other XXX half the a to
the Success in quarter broad-based. was
at and robust by While global solid, remained in a demand cold season. strong part a consumption driven high, European four-year consumer very is is
with XX% Our share versus in ago a takeaway Compeed brand up demand strong year the continues gains, consumer and to see quarter.
insect and positive such market year, last continuing are the drivers our recover CSCI as anti-parasites share of gaining trends oral logistics areas, experienced the and Other care repellents, growth. categories U.S., businesses and chain and positive. supply are sales were In very in consumption dynamics growing to and from
compete number and and distribution NRT robust XX% digestive new in OTC, Perrigo gained U.S. in two driven a products in. we share we grew the the categories, by And the consumption health categories gains. care share recaptured in and higher position in Oral quarter, margin
in points. X.X% was the a OTC U.S. XX%, note, basis up organic quarter Of U.S. gross up OTC year and margin growth versus was ago, XXX
U.S. category. the currency of Looking of segments at our organically. is but is XX% business, top constant quarter, Many and we every in they nearly more the line revenues, XX% growth our grew in its detail, product stride. U.S. business bit so are both really a in hitting based, which achieved The nearly toward CSCI, strong XX% gravitate investors
The strategic come was due cough, strong high noted HRA, cold, brands, from stickiness and increases, the price together from greater of the leverage EU gains, CSCI consumption beautifully. strong really has incidences and I to HRA, our Pan-European brands. of the share the The business flu, just
again SKU experienced and Rationalization purposely consumer products We solid divestitures. the Program for low-margin when from especially demand from also in discontinued our you once adjust U.S.,
business than QX customers unusual. shipments see the that inventories grew that's a in below something unfavorable total, SKU levels during impact basis as not reduced quarter, fourth from quarter in OTC greater we replenished the U.S. often Our to were including Rationalization. as XXXX they the point noting normal worth customers X% and were it's consumption in in XXX It's exited and
and category the our acquisition which discussed. Compeed movements which other Minoxidil in the and the skin the notable capacity care, I just HRA, addition benefited from increased hair manufacturing which of health, the Mederma women's the addition from Other care, brands, U.S., benefited LXX in of an products for from oral of brands quarter regrowth and included
the in CSCA an quarter, our Net by in on GoodStart business, Infant Contract driven minute and Formula the sales growth from Let's strong spend a grew million $XX XX% business. in Acquisition. sales the Nutrition additional
As this shortage. recall is Formula. an includes a a GoodStart benefited year-ago impact sales infant SoothePro $X very $XX growth against million compared due strong formula GoodStart the period The Acquisition a the from from of to Gerber Infant unfavorable benefited that of the reminder, million of certain voluntary lots
our here. to into manufacturing has more powdered the cost and members safety issued of formula. formula. letter of and to Let assist infant little strategy infant improving This FDA formula March letter detail significant in go a a impact industry In national a the XXXX, to on a me produce microbiological released infant
one, Of for hold modernize formula new to we further processes course, refinements evolving two, are, response to to supports manufacturing Perrigo further including and food and significant regulatory infrastructure sanitation our to promote infant procedures, safety and, FDA babies. nutrition and procedures, adjustments strategy and mission In and its modifying times, investments evaluating ensure quality FDA's expectations, our more. to in making
new will even cost offset per price brands. XX% negatively a to these significantly approximate national substantial cost infant increase, deliver price requirements as the As the Perrigo we said, will raise products compared that with the impact actions formula. of consumers after savings ounce increase. producing But will regulatory of anticipate and an store-brand these supply The I be
much transformed future. say has together. past Let me enough pull years all the how and about Perrigo excited over I our I this few can't am how
and continue Our market strong fundamentals we getting are stronger to share. as win
big accretive acquisitions impact. strategic a are Our having
years. Our optimize three outsized expanding, and to the our continue we next over gross and operations strategic to investments is drive accelerate growth our margin
discuss before turn I'll I'll the to Q&A. over the end and more to our wrap call Eduardo? come back to CFO in in that, financials With detail, up